US Patent Issued to C4 Therapeutics on July 29 for "Isoindolinone and indazole compounds for the degradation of EGFR" (American, French, Swiss Inventors)

ALEXANDRIA, Va., July 30 -- United States Patent no. 12,371,442, issued on July 29, was assigned to C4 Therapeutics Inc. (Watertown, Mass.).

"Isoindolinone and indazole compounds for the degradation of EGFR" was invented by Christopher G. Nasveschuk (Stoneham, Mass.), Martin Duplessis (Somerville, Mass.), Jae Young Ahn (Somerville, Mass.), Alexander W. Hird (Belmont, Mass.), Ryan E. Michael (Erie, Colo.), Kiel Lazarski (Boston), Yanke Liang (Belmont, Mass.), Georg Jaeschke (Basel, Switzerland), Antonio Ricci (Biel-Benken, Switzerland), Annick Goergler (Colmar, France) and Daniel Rueher (Raedersdorf, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides compounds that degrade the epider...